Abstract
Background/Aim: We have previously reported that caffeine (CAF) can enhance chemotherapy efficacy of bone and soft-tissue sarcoma established cell lines via cell-cycle perturbation. We subsequently tested the combination of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, with caffeine on established human osteosarcoma cells in vitro. Both VPA and CAF caused concentration-dependent cell death of the osteosarcoma cell lines in vitro, and their combination was synergistic. We subsequently established patient-derived cell lines from undifferentiated pleomorphic sarcoma (UPS) and rhabdomyosarcoma (RMS), both of which are recalcitrant cancers. These cell lines are termed AC-UPS01 and AC-RMS01, respectively. Materials and Methods: In the present study, we tested CAF and VPA and their combination on the two patientderived sarcoma cell lines. Cell survival after a 72 h exposure to each drug was determined by the WST-8 assay. IC50 values were calculated for each drug. Results: CAF and VPA caused concentration-dependent cytocidal efficacy for both cell lines. The IC50 for CAF for AC-UPS01 was 2.02 ± 0.22 mM. The IC50 for VPA for AC-UPS01 was 9.54 ± 1.44 mM. The IC50 for CAF for AC-RMS01 was 2.37 ± 0.48 mM. The IC50 for VPA for ACRMS01 was 2.13 ± 0.20 mM. Synergistic efficacy of combination treatment of CAF and VPA was also observed for both cell lines. Conclusion: The results of the present study suggest that CAF and VPA may be useful in the treatment of recalcitrant sarcoma.
Original language | English |
---|---|
Pages (from-to) | 4081-4084 |
Number of pages | 4 |
Journal | Anticancer research |
Volume | 37 |
Issue number | 8 |
DOIs | |
Publication status | Published - 2017 Aug |
Externally published | Yes |
Keywords
- Caffeine
- Cell kill
- Patient-derived cell lines
- RMS
- Rhabdomyosarcoma
- Synergy
- UPS
- Undifferentiated pleomorphic sarcoma
- Valproic acid
ASJC Scopus subject areas
- Oncology
- Cancer Research